ClinicalTrials.gg
CompletedNCT01561313Updated Feb 20, 2014Results posted

Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.

A Phase 2 interventional study of Adalimumab in Rheumatoid Arthritis, sponsored by AbbVie (prior sponsor, Abbott). Completed at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-20.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
64th of 87
64 · median 160
Started
2012
with 3 others
Phase 2
9 of 87
2 open now
Registered
48th of 87
by date
Lead sponsor
7 of 87
AbbVie (prior sponsor, Abbott)

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 64th largest by enrollment, is one of 4 that started in 2012, is one of 9 in phase 2, and was the 48th registered.

Arthritis, Rheumatoid

3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This study will compare injection site pain levels between current Humira® formulation versus a new formulation of Humira in patients with Rheumatoid Arthritis (RA), who are either currently on a stable dose (minimum six consecutive doses) of on-label Humira or biological naïve who will be prescribed on-label Humira as treatment for their Rheumatoid Arthritis. The study is being conducted in two countries, Belgium (3 sites) and the Czech Republic (3 sites).

Read the detailed description

64 participants were randomized, 63 received at least one dose of the study drug, and 62 participants were analyzed for injection site-related pain. 63 participants were analyzed for other safety analyses. Two participants, who were randomized to the Current formulation adalimumab/New formulation of adalimumab arm of the study were excluded from the analysis of injection site-related pain. One participant received one dose of study drug and discontinued because of an adverse event, while the other discontinued before receiving any study drug.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • On label Humira users
  • Pain
  • Rheumatoid Arthritis,
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subject age 18 years or older, who requires Humira 40 mg SC every other week (eow) or every week (ew) for the treatment of rheumatoid arthritis, in accordance with the local Humira label.
  • Subject must be a current, on-label user of Humira who rates his/her average Humira injection site related pain as at least 3 cm on a pain Visual Analogue Scale and has had at least 6 consecutive doses of Humira prior to Screening, or a biologic naïve subject who requires initiation of on-label treatment with Humira.
  • Subject has diagnosis of rheumatoid arthritis (RA) as defined by the 1987 revised ACR classification criteria or the ACR/EULAR 2010 criteria,
  • Female subjects are either not of , defined as for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy and/or hysterectomy), or are practicing at least one method of throughout the study and for at least 70 days after the last dose of study drug.
  • All female subjects of childbearing potential must have a negative test for pregnancy on a serum sample at Screening and prior to study drug dosing on a urine sample obtained at Visit 1.

Exclusion criteria

Exclusion Criteria:

  • Subject has been treated with any drug of a chemical or biologic nature within a minimum of 30 days or 5 half-lives (whichever is longer) of the drug prior to Visit 1.
  • Any infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to Visit 1 or oral anti-infectives within 14 days prior to Visit 1.
  • Prior exposure to natalizumab (Tysabri®) or efalizumab (Raptiva®).
  • Known to adalimumab or its .
  • History of demyelinating disease (including myelitis) or neurologic symptoms suggestive of demyelinating disease.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
64 participants (actual)

Study arms

  • Active comparator
    Current formulation adalimumab

    One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe

    Biological: Adalimumab

  • Experimental
    New formulation of adalimumab

    One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe

    Biological: Adalimumab

Interventions

  • BiologicalAdalimumab

    Subcutaneously 40 mg every other week (EOW) or every week (EW) (as dosing requires)

    Also known as: Humira, ABT-D2E7

06

What researchers measure

Primary outcomes

  1. Mean Injection Site Pain on a Visual Analogue Scale (VAS)

    The primary response variable is participant's immediate pain of injection on a visual analogue scale (VAS) of 0 to 10 (cm), with 0 representing no pain and 10 representing the worst possible pain.

    Time frame: Immediately after injection

Secondary outcomes

  1. Mean Injection Site Pain on a Visual Analogue Scale (VAS)

    The secondary response variable is participant's pain of injection on a visual analogue scale (VAS) of 0 to 10 (cm) recorded 15 minutes after the injection, with 0 representing no pain and 10 representing the worst possible pain.

    Time frame: 15 minutes post injection

  2. Percentage of Participants With no Hemorrhage/Petechiae in the Draize Scale

    Hemorrhage/petechiae (bleeding/spots of bleeding underneath the skin) was assessed.

    Time frame: 10 minutes and 30 minutes after injection

  3. Percentage of Participants With no Erythema in the Draize Scale

    Erythema (redness) was assessed.

    Time frame: 10 minutes and 30 minutes after injection

  4. Percentage of Participants With no Edema in the Draize Scale

    Edema (swelling) was assessed.

    Time frame: 10 minutes and 30 minutes after injection

  5. Percentage of Participants With no Pruritus in the Draize Scale

    Pruritus (itching) was assessed.

    Time frame: 10 minutes and 30 minutes after injection

  6. Number of Participants With Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment.

    Time frame: Adverse events were collected from the time of study drug administration until 70 days following discontinuation of study drug. Serious Adverse Events were collected from the time the participant signed the informed consent.

07

Results

Posted Feb 20, 2014

Participant flow

Participant flow — Overall Study
MilestoneCurrent Formulation Adalimumab/New Formulation of AdalimumabNew Formulation of Adalimumab/Current Formulation Adalimumab
Started3331
Completed3131
Not completed20
Withdrew: Withdrawal by subject10
Withdrew: Adverse event and withdrawal by subject10

Outcome measures

PrimaryMean Injection Site Pain on a Visual Analogue Scale (VAS)

The primary response variable is participant's immediate pain of injection on a visual analogue scale (VAS) of 0 to 10 (cm), with 0 representing no pain and 10 representing the worst possible pain.

Time frame:
Immediately after injection
Reported as:
Mean · cm
Mean Injection Site Pain on a Visual Analogue Scale (VAS)
cmCurrent Formulation AdalimumabNew Formulation of Adalimumab
Mean Injection Site Pain on a Visual Analogue Scale (VAS)3.3 ± 2.111.6 ± 2.09
SecondaryMean Injection Site Pain on a Visual Analogue Scale (VAS)

The secondary response variable is participant's pain of injection on a visual analogue scale (VAS) of 0 to 10 (cm) recorded 15 minutes after the injection, with 0 representing no pain and 10 representing the worst possible pain.

Time frame:
15 minutes post injection
Reported as:
Mean · cm
Mean Injection Site Pain on a Visual Analogue Scale (VAS)
cmCurrent Formulation AdalimumabNew Formulation of Adalimumab
Mean Injection Site Pain on a Visual Analogue Scale (VAS)1.0 ± 1.520.9 ± 1.66
SecondaryPercentage of Participants With no Hemorrhage/Petechiae in the Draize Scale

Hemorrhage/petechiae (bleeding/spots of bleeding underneath the skin) was assessed.

Time frame:
10 minutes and 30 minutes after injection
Reported as:
Number · Percentage of Participants
Percentage of Participants With no Hemorrhage/Petechiae in the Draize Scale
Percentage of ParticipantsCurrent Formulation AdalimumabNew Formulation of Adalimumab
10 minutes91.996.8
30 minutes98.498.4
SecondaryPercentage of Participants With no Erythema in the Draize Scale

Erythema (redness) was assessed.

Time frame:
10 minutes and 30 minutes after injection
Reported as:
Number · Percentage of Participants
Percentage of Participants With no Erythema in the Draize Scale
Percentage of ParticipantsCurrent Formulation AdalimumabNew Formulation of Adalimumab
10 minutes69.464.5
30 minutes75.872.6
SecondaryPercentage of Participants With no Edema in the Draize Scale

Edema (swelling) was assessed.

Time frame:
10 minutes and 30 minutes after injection
Reported as:
Number · Percentage of Participants
Percentage of Participants With no Edema in the Draize Scale
Percentage of ParticipantsCurrent Formulation AdalimumabNew Formulation of Adalimumab
10 minutes80.683.9
30 minutes85.585.5
SecondaryPercentage of Participants With no Pruritus in the Draize Scale

Pruritus (itching) was assessed.

Time frame:
10 minutes and 30 minutes after injection
Reported as:
Number · Percentage of Participants
Percentage of Participants With no Pruritus in the Draize Scale
Percentage of ParticipantsCurrent Formulation AdalimumabNew Formulation of Adalimumab
10 minutes10098.4
30 minutes98.498.4
SecondaryNumber of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment.

Time frame:
Adverse events were collected from the time of study drug administration until 70 days following discontinuation of study drug. Serious Adverse Events were collected from the time the participant signed the informed consent.
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsCurrent Formulation AdalimumabNew Formulation of Adalimumab
Number of Participants With Adverse Events (AEs)21

Adverse events

Collected over Adverse events were collected from the time of study drug administration until 70 days following discontinuation of study drug. In addition, SAEs were collected from the time the participant signed the study-specific informed consent.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Current Formulation Adalimumab—0/63 (0%)2/63 (3.2%)
New Formulation of Adalimumab—0/62 (0%)1/62 (1.6%)
Most frequent other events
Most frequent other events
EventCurrent Formulation AdalimumabNew Formulation of Adalimumab
PROTEIN URINE PRESENTInvestigations0/631/62
PHARYNGITISInfections and infestations1/630/62
RASH ERYTHEMATOUSSkin and subcutaneous tissue disorders1/630/62

Baseline characteristics

63 participants received at least one dose of the study drug, and 62 participants were analyzed for injection site-related pain. 63 participants were analyzed for other safety analyses.

Age, Continuous
Age, Continuous(years)Current Formulation Adalimumab/New Formulation of AdalimumabNew Formulation of Adalimumab/Current Formulation AdalimumabTotal
Mean51.1 ± 12.5758.6 ± 13.5354.8 ± 13.49
Sex: Female, Male
Sex: Female, Male(Participants)Current Formulation Adalimumab/New Formulation of AdalimumabNew Formulation of Adalimumab/Current Formulation AdalimumabTotal
Female212142
Male101020
08

Study locations

6 sites
  • Site Reference ID/Investigator# 63357
    Genk, 3600, Belgium
  • Site Reference ID/Investigator# 63359
    Ghent, 9000, Belgium
  • Site Reference ID/Investigator# 63360
    Ghent, 9000, Belgium
  • Site Reference ID/Investigator# 63363
    Brno, 63800, Czech Republic
  • Site Reference ID/Investigator# 63362
    Prague 2, 128 50, Czech Republic
  • Site Reference ID/Investigator# 63361
    Uherske Hradiste, 686 01, Czech Republic
09

References and documents

Publications

  • Nash P, Vanhoof J, Hall S, Arulmani U, Tarzynski-Potempa R, Unnebrink K, Payne AN, Cividino A. Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8 mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis. Rheumatol Ther. 2016 Dec;3(2):257-270. doi: 10.1007/s40744-016-0041-3. Epub 2016 Aug 18. PubMed 27747583 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2012
First posted
Mar 23, 2012
Start
Mar 2012
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Results first posted
Feb 20, 2014
Last update
Feb 20, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01561313
Responsible party
Sponsor
First posted
Mar 23, 2012
Start date
Mar 2012
Primary completion
Nov 2012
Completion
Nov 2012
Results posted
Feb 20, 2014
Last update
Feb 20, 2014

Study contacts

Andrew Payne, PhD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion